Cargando…
Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
Objectives. Prophylaxis regimens for severe hemophilia A allowing more flexible dosing while maintaining efficacy may improve adherence and decrease the cost of prophylaxis. Here, we compared the clinical effectiveness of once- or twice-weekly versus ≥3-times-weekly prophylaxis with sucrose-formulat...
Autores principales: | Humphries, Thomas J., Rauchensteiner, Stephan, Tückmantel, Claudia, Pieper, Alexander, Maas Enriquez, Monika, Mathew, Prasad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556870/ https://www.ncbi.nlm.nih.gov/pubmed/26356675 http://dx.doi.org/10.1155/2015/431268 |
Ejemplares similares
-
Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
por: Kavakli, K, et al.
Publicado: (2015) -
Eight-Year Postmarket Safety Surveillance of Delayed Complications With a Flexible Lip Filler
por: Cohen, Joel L., et al.
Publicado: (2022) -
Ten-Year Global Postmarket Safety Surveillance of Delayed Complications With a Flexible Cheek Filler
por: Cohen, Joel L., et al.
Publicado: (2022) -
Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
por: Marzolini, Maria A. V., et al.
Publicado: (2021) -
BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
por: Lalezari, Shadan, et al.
Publicado: (2019)